


Capped CRM Conjugate

Figure 1



Lys
LysCOCH2CysteamneNAc
LysCOCH2CysPeptide
Acid Hydroylsis
Free Amino Acids
including recovery of all
Lysines and;
CO2H
HO2C
S
NH2
S-Carboxymethylcysteine,
from Cysteine at Conjugation Sites
HO2C
S
NH2
S-Carboxymethylcysteamine,
from Cysteamine at Capped Sites

Figure 2



12
10
8
6
4
2
0
Degree of Conjugation (CMC/Mole)
7
7.5
8
8.5
9
9.5
10
pH
Abeta 1-5/CRM
Abeta 1-7/CRM

Figure 3



Degree of Conjugation (CMC/Mole)
20
18
16
14
12
10
8
6
4
2
0
0.0
20.0
40.0
60.0
80.0
100.0
Peptide:CRM (mole basis)
Abeta 1-7/CRM
Abeta 1-5/CRM

Figure 4



25
20
15
10
5
0
0
0.2
0.4
0.6
0.8
1
Number of lysines modified per CRM
Peptide:CRM (w/w)
CMC
CMCA
Total

Figure 5



25
20
15
10
5
0
0
0.5
1
1.5
Number of Modified Lysines (CMC/Mole)
Peptide:CRM ratio
CMC
CMCA
Total

Figure 6



Day 36 Titers
Titer
100000
10000
1000
100
10
1
GMT=223
GMT=1734
GMT=10110
GMT=2134
GMT=13330
GMT=15980
GMT=17090
75AN1792/100QS-21
300AN1792/100QS-21
1-7CRM/QS-21
1-5CRM/Alum
1-7CRM/Alum
1-5CRM/RC529
1-7CRM/RC529
Treatment Group

Figure 7



Day 64 Titers
Titer
1000000
100000
10000
1000
100
GMT=1329
GMT=3953
GMT=30310
GMT=1689
GMT=5652
GMT=21640
GMT=69910
75AN1792/100QS-21
300AN1792/100QS-21
1-7CRM/QS-21
1-5CRM/Alum
1-7CRM/Alum
1-5CRM/RC529
1-7CRM/RC529
Treatment Group

Figure 8



Titers by Day
125000
100000
75000
50000
25000
0
Titer
Day 29
Day 36
Day 57
Day 64
1-7CRM/QS-21
1-5CRM/Alum
1-7CRM/Alum
1-5CRM/RC529
1-7CRM/RC529
Treatment Group

Figure 9




Figure 10